ImmunoGen racked up another multitarget deal involving its maytansinoid Targeted Antibody Payload (TAP) technology, this time with US drug powerhouse Lilly, which plans to use the technology to develop antibody-drug conjugate (ADC) anticancer therapeutics.
Indianapolis-based Lilly is paying ImmunoGen $20 million up front, with the Waltham, Massachusetts-based biotech potentially garnering $200 million in milestones,...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

